Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gallus BioPharmaceuticals Utilizes ambr15 Micro Bioreactor

Published: Tuesday, May 06, 2014
Last Updated: Tuesday, May 06, 2014
Bookmark and Share
To rapidly optimize process development of novel antibodies and biosimilars.

TAP Biosystems has announced that its ambr15 micro bioreactor system is being used at the leading US-based Contract Manufacturing Organization (CMO), Gallus BioPharmaceuticals, LLC (“Gallus”) to optimize process development and clone selection of novel antibody therapeutics and biosimilars.

Gallus’ scientists are using the ambr15 micro bioreactor in their new, Process Development facility in St. Louis, Missouri. The system is being used for clone selection programmes to determine which CHO cell lines are stable and produce the highest titre mAbs.

They are also using the ambr system to optimize media selection and feed strategies for these mAbs, which are being developed as antibody therapeutics and biosimilars for some of the world’s top pharma and biotech firms.

Matt Caple, Scientific Director of Cell Culture Development at Gallus said: “Our clients want high yielding, pure biotherapeutic antibodies that they can take into clinical trials as quickly as possible. However, they often come to us without any process development history for their mAb clones and we have to ensure we build them a robust process. We used to do this with multiple shake flask and benchtop scale bioreactor runs - in one media development project we performed 1000 shake flasks runs - however, we knew we couldn’t continue to work at this labour-intensive scale. So we assessed a number of bioreactor models and concluded that the ambr15 system was the right option for us.”

Caple added: “We have now been working with our ambr15 for six months and, from our comparison studies, have seen the titre results of our mAbs correlate well with those we obtained in 50L bioreactors. We are currently using ambr15 routinely for our bioprocess characterization work and are looking at using it for perfusion culture modelling. For us, ambr is ‘game changing’ technology, so much so that we are now running it around the clock and are considering buying a second system.”

Dr Barney Zoro, ambr15 Product Manager at TAP Biosystems stated: "We’re delighted that Gallus has integrated the ambr15 system so seamlessly into their new Process Development facility. Their confidence in the system shows scientists that ambr15 is the proven choice for helping to deliver robust, high-performance cell culture processes, especially where biotech and pharma clients are imposing stringent timelines and product quality targets.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck and TAP Biosystems Finalists for “Best Collaboration Award”
Recognizing ambr250 as a breakthrough technology for process development.
Wednesday, October 08, 2014
TAP and Gallus Co-host Free Webinar
Explaining the benefits of using ambr15 microbioreactors for DoE.
Wednesday, October 01, 2014
New Webinars Explore Feed Strategy Challenges Using Mini Bioreactors
Detailing how to achieve consistent feeding regimes for reproducible scale-up.
Thursday, September 25, 2014
New Webinar on Mimicking Perfusion Culture Using Micro Bioreactors
Presents validation data for improving media screening and process optimization.
Friday, February 14, 2014
TAP Biosystems Presents New Data on 3D Cell Culture Research
Discussing the application of RAFT 3D models in oncology, toxicology and neuroscience cell-based screening programmes.
Monday, January 20, 2014
TAP Biosystems Partners with Life Technologies on Protein Expression Platform
The companies will collaborate to develop a cost-efficient, high throughput protein expression platform.
Tuesday, January 15, 2013
Collaboration between TAP Biosystems and UCL to Develop Biomimetic 3D Cancer Models
TAP Biosystems announced new collaboration to develop solid tumour tissue models using its RAFT 3D cell culture system for use in drug discovery applications.
Friday, October 12, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!